Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

With Multiple Takeover Offers, Stada Conducts Open Bidding Process

By Stada Arzneimittel AG | February 27, 2017

Stada conducts structured and open bidding process with all interested parties.

This weekend, the executive and supervisory boards of Stada Arzneimittel AG have converted the ongoing open-minded talks with all interested parties started on February 13 into a structured bidding process.

The transparent and fair process which is open to further interested parties ensures that all potential bidders receive the same level of information and will have the same opportunity to present their plans for Stada. For this purpose, a data room has been established and the potential bidders — three to date — have been invited to conduct multistage due diligence. 

In the interest of all shareholders and stakeholders of the company, further potential for value enhancement shall be presented in this process in order to be reflected in possible offer prices. Moreover, the value of the strategic concepts of the interested parties as well as their willingness to grant protective mechanisms for stakeholders will also be examined. The executive and supervisory boards intend to conduct a thorough process that will be finalized efficiently to the best interest of the company. Stada will keep the capital market regularly updated on tangible developments.

Stada Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. Stada consistently focuses on a multi-pillar strategy of generics and branded products (OTC) with an increasingly international market orientation.

The group is the only independent generics producer in Germany. Worldwide, Stada is represented in more than 30 countries with more than 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany.

In financial year 2015, Stada achieved group sales of Euro 2,115.1 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 389.4 million and adjusted net income of Euro 165.8 million. As of December 31, 2015, Stada employed 10,532 people worldwide.

(Note: Euro 1 = $1.06 on February 27, 2017)

(Source: Stada Arzneimittel AG)


Filed Under: Drug Discovery

 

Related Articles Read More >

EpicentRx
A next-gen vaccine that could help end COVID-19 whack-a-mole 
Dotmatics
How Dotmatics aims to help reduce the drug discovery failure rate
Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50